uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register
Umea Univ Hosp, Dept Clin Sci, Umea, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centre for Clinical Research, County of Västmanland.
Lund Univ, Dept Radiol, Inst Translat Med, Malmo, Sweden..
Blekinge Hosp, Register Ctr South, Karlskrona, Sweden..
Show others and affiliations
2017 (English)In: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768, Vol. 95, no 8, p. 787-795Article in journal (Refereed) Published
Abstract [en]

Purpose: To present Swedish Macula Register (SMR) data regarding treatment of neovascular age-related macular degeneration (AMD) in clinical practice since 2008.

Methods: A retrospective register-based study was conducted. Evaluation of baseline demographics, visual outcome and number of injections during this period is presented.

Results: Mean age at diagnosis was 79(SD) 8years; 65% were female. The proportion of patients with <2months' duration of symptoms increased from 26% in 2008 to 41% in 2014 (p=0.001). Mean visual acuity (VA) at baseline increased from 54.3 +/- 15.0 early treatment diabetic retinopathy study (ETDRS) letters in 2008 to 57.8 +/- 15.6 letters in 2014 (CI95 2.6; 4.3; p<0.001). Mean VA after 1year of treatment increased from 57.8 +/- 17.7 ETDRS letters for patients who started the treatment in 2008 to 62.8 +/- 16.4 ETDRS letters in patients starting treatment in 2014 (CI95 2.67; 4.64; p<0.001). During all study years, the proportion of patients with an improvement in VA of between 5 and 15 letters was around 30%, while 14% had VA improvement of more than 15 letters. The mean number of injections during the first treatment year increased from 4.3 +/- 1.9 in 2008 to 5.9 +/- 2.9 in 2014 (CI95 1.40; 1.67; p<0.001). Seven-year follow-up of 322 eyes showed a mean change of -1 letters from baseline, with a mean of 21 injections for the entire period.

Conclusion: The duration of symptoms before treatment decreased, while VA at baseline and after 1year of treatment increased over the years and so did the number of injections. Long-term follow-up demonstrated stable VA.

Place, publisher, year, edition, pages
2017. Vol. 95, no 8, p. 787-795
Keywords [en]
age-related macular degeneration, anti-vascular endothelial growth factor, anti-VEGF, ETDRS, neovascular AMD, Swedish Macula Register
National Category
Ophthalmology
Identifiers
URN: urn:nbn:se:uu:diva-343909DOI: 10.1111/aos.13539ISI: 000417645900022PubMedID: 28834299OAI: oai:DiVA.org:uu-343909DiVA, id: diva2:1187151
Available from: 2018-03-02 Created: 2018-03-02 Last updated: 2018-03-08Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Granstam, Elisabet

Search in DiVA

By author/editor
Granstam, Elisabet
By organisation
Centre for Clinical Research, County of Västmanland
In the same journal
Acta Ophthalmologica
Ophthalmology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 2 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf